360 related articles for article (PubMed ID: 28834809)
21. Uterine Adenosarcoma: a Review.
Nathenson MJ; Ravi V; Fleming N; Wang WL; Conley A
Curr Oncol Rep; 2016 Nov; 18(11):68. PubMed ID: 27718181
[TBL] [Abstract][Full Text] [Related]
22. The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study.
Guerini-Rocco E; Hodi Z; Piscuoglio S; Ng CK; Rakha EA; Schultheis AM; Marchiò C; da Cruz Paula A; De Filippo MR; Martelotto LG; De Mattos-Arruda L; Edelweiss M; Jungbluth AA; Fusco N; Norton L; Weigelt B; Ellis IO; Reis-Filho JS
J Pathol; 2015 Oct; 237(2):166-78. PubMed ID: 26011570
[TBL] [Abstract][Full Text] [Related]
23. Adenosarcoma of the uterus: a clinicopathologic, DNA flow cytometric, p53 and mdm-2 analysis of 11 cases.
Blom R; Guerrieri C
Int J Gynecol Cancer; 1999 Jan; 9(1):37-43. PubMed ID: 11240741
[TBL] [Abstract][Full Text] [Related]
24. Mesodermal (müllerian) adenosarcoma of the ovary: a clinicopathologic analysis of 40 cases and a review of the literature.
Eichhorn JH; Young RH; Clement PB; Scully RE
Am J Surg Pathol; 2002 Oct; 26(10):1243-58. PubMed ID: 12360039
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical markers and the clinical course of adenosarcoma: a series of seven cases.
Omi M; Tonooka A; Chiba T; Tanaka Y; Fusegi A; Aoki Y; Nomura H; Kanao H; Takazawa Y
Diagn Pathol; 2020 Sep; 15(1):119. PubMed ID: 32972432
[TBL] [Abstract][Full Text] [Related]
26. The Overexpression of Programmed Death-Ligand 2 in Uterine Adenosarcoma: Correlation with High-Grade Morphology, Mutant Type TP53 Expression and Clinical Outcomes.
Ok Atılgan A; Yılmaz Akçay E; Özen Ö; Haberal Reyhan AN; Ayhan A
Int J Surg Pathol; 2023 Jun; 31(4):352-364. PubMed ID: 35466759
[TBL] [Abstract][Full Text] [Related]
27. Müllerian adenosarcomas of the uterus with sarcomatous overgrowth. A clinicopathological analysis of 10 cases.
Clement PB
Am J Surg Pathol; 1989 Jan; 13(1):28-38. PubMed ID: 2535774
[TBL] [Abstract][Full Text] [Related]
28. Microsatellite Instability Status and the Expression of p16 and Cyclin D1 Proteins in Uterine Adenosarcoma and Their Clinicopathological Significance.
Atilgan AO; Akcay EY; Ozen O; Haberal Reyhan AN; Ayhan A
Turk Patoloji Derg; 2023; 39(1):31-41. PubMed ID: 35876683
[TBL] [Abstract][Full Text] [Related]
29. The Importance of Lymphovascular Invasion in Uterine Adenosarcomas: Analysis of Clinical, Prognostic, and Treatment Outcomes.
Nathenson MJ; Conley AP; Lin H; Fleming N; Lazar A; Wang WL; Ravi V
Int J Gynecol Cancer; 2018 Sep; 28(7):1297-1310. PubMed ID: 30044322
[TBL] [Abstract][Full Text] [Related]
30. Primary vaginal adenosarcoma with sarcomatous overgrowth.
Toyoshima M; Akahira J; Moriya T; Hayakawa S; Yaegashi N
Gynecol Oncol; 2004 Dec; 95(3):759-61. PubMed ID: 15582000
[TBL] [Abstract][Full Text] [Related]
31. Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival.
Krivak TC; Seidman JD; McBroom JW; MacKoul PJ; Aye LM; Rose GS
Gynecol Oncol; 2001 Oct; 83(1):89-94. PubMed ID: 11585418
[TBL] [Abstract][Full Text] [Related]
32. The expression of epidermal growth factor receptor, HER-2/Neu, p53, and Ki-67 antigen in uterine malignant mixed mesodermal tumors and adenosarcoma.
Swisher EM; Gown AM; Skelly M; Ek M; Tamimi HK; Cain JM; Greer BE; Muntz HG; Goff BA
Gynecol Oncol; 1996 Jan; 60(1):81-8. PubMed ID: 8557233
[TBL] [Abstract][Full Text] [Related]
33. Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course.
Watanabe T; Katayama Y; Yoshino A; Komine C; Yokoyama T
Clin Cancer Res; 2003 Oct; 9(13):4884-90. PubMed ID: 14581362
[TBL] [Abstract][Full Text] [Related]
34. Uterine müllerian adenosarcoma with sarcomatous overgrowth and lung metastasis in a 25-year-old woman.
Choi YJ; Jung MH; Park YK; Lee BY; Huh CY
Eur J Gynaecol Oncol; 2011; 32(1):91-4. PubMed ID: 21446335
[TBL] [Abstract][Full Text] [Related]
35. BCOR Expression in Mullerian Adenosarcoma: A Potential Diagnostic Pitfall.
Muthukumarana V; Fix DJ; Stolnicu S; Park KJ; Soslow RA; Benayed R; Ladanyi M; Antonescu CR; Chiang S
Am J Surg Pathol; 2020 Jun; 44(6):765-770. PubMed ID: 32011345
[TBL] [Abstract][Full Text] [Related]
36. Mullerian adenosarcomas: an immunophenotypic analysis of 35 cases.
Soslow RA; Ali A; Oliva E
Am J Surg Pathol; 2008 Jul; 32(7):1013-21. PubMed ID: 18469708
[TBL] [Abstract][Full Text] [Related]
37. Prognostic factors for uterine adenosarcoma: a review.
Nathenson MJ; Conley AP
Expert Rev Anticancer Ther; 2018 Nov; 18(11):1093-1100. PubMed ID: 30169984
[TBL] [Abstract][Full Text] [Related]
38. Two unusual presentations of müllerian adenosarcoma: case reports, literature review, and treatment considerations.
Gollard R; Kosty M; Bordin G; Wax A; Lacey C
Gynecol Oncol; 1995 Dec; 59(3):412-22. PubMed ID: 8522267
[TBL] [Abstract][Full Text] [Related]
39. Adenofibroma and adenosarcoma of the uterus: a clinicopathologic study of 35 cases.
Zaloudek CJ; Norris HJ
Cancer; 1981 Jul; 48(2):354-66. PubMed ID: 6263458
[TBL] [Abstract][Full Text] [Related]
40. Uterine adenosarcomas: a dual-institution update on staging, prognosis and survival.
Bernard B; Clarke BA; Malowany JI; McAlpine J; Lee CH; Atenafu EG; Ferguson S; Mackay H
Gynecol Oncol; 2013 Dec; 131(3):634-9. PubMed ID: 24135678
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
